Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accounts Payables: 2019-2025

Historic Accounts Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $3.7 million.

  • Allogene Therapeutics' Accounts Payables fell 32.82% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 32.82%. This contributed to the annual value of $5.4 million for FY2024, which is 8.53% down from last year.
  • Allogene Therapeutics' Accounts Payables amounted to $3.7 million in Q3 2025, which was down 23.75% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Accounts Payables peaked at $14.9 million during Q1 2021, and registered a low of $3.7 million during Q3 2025.
  • For the 3-year period, Allogene Therapeutics' Accounts Payables averaged around $7.3 million, with its median value being $5.8 million (2024).
  • In the last 5 years, Allogene Therapeutics' Accounts Payables spiked by 106.63% in 2021 and then tumbled by 62.50% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Accounts Payables (Quarterly) stood at $10.3 million in 2021, then spiked by 35.45% to $13.9 million in 2022, then slumped by 57.54% to $5.9 million in 2023, then fell by 8.53% to $5.4 million in 2024, then crashed by 32.82% to $3.7 million in 2025.
  • Its Accounts Payables was $3.7 million in Q3 2025, compared to $4.9 million in Q2 2025 and $5.1 million in Q1 2025.